Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005, HepatoBiliary Surgery and Nutrition, September 2018, AME Publishing Company,
DOI: 10.21037/hbsn.2018.08.03.
You can read the full text:
Contributors
The following have contributed to this page